Teva's 1st-qtr profit more than triples
World generic drug giant Teva Pharmaceutical Industries' first-quarter 2009 profit more than tripled year-on-year to $451.0 million, as revenue jumped 22% to $3.15 billion, boosted by sales of generic versions of Swiss drug major Novartis' Lotrel (amlodipine/benazepril) and Medicis' Solodyn (minocycline HCl).
The Israeli firm said drug sales in North America jumped 36% to $1.86 billion, accounting for 62% of total pharmaceutical revenues. Sales in the region were boosted by its version of Yasmin (drospirenone and ethinyl estradiol), Protonix (pantoprazole) and Duragesic (fentanyl citrate). Total European sales rose 4% to $692.0 million.
Turnover of Teva's branded multiple sclerosis drug Copaxone (glatiramer acetate injection) jumped 15% to $621.0 million, boosted by a 38% rise in the USA. Global in-market sales of Agilect/Azilect (rasagiline) increased 50% to $55.0 million, as the Parkinson's disease drug continued to increase its market share in Europe and the USA.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze